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Abstract
Background: Antihypertensive drug choices and treatment levels are not in accordance with the existing
guidelines. We aimed to assess the impact of a guideline implementation intervention on antihypertensive drug
prescribing.
Methods: In this controlled before and after study, the effects of a multifaceted (education, audit and feedback,
local care pathway) quality programme was evaluated. The intervention was carried out in a health centre between
2002 and 2003. From each health care unit (n = 31), a doctor-nurse pair was trained to act as peer facilitators in
the intervention.
All antihypertensive drugs prescribed by 25 facilitator general practitioners (intervention GPs) and 53 control GPs
were retrieved from the nationwide Prescription Register for three-month periods in 2001 and 2003. The
proportions of patients receiving specific antihypertensive drugs and multiple antihypertensive drugs were
measured before and after the intervention for three subgroups of hypertension patients: hypertension only, with
coronary heart disease, and with diabetes.
Results: In all subgroups, the use of multiple concurrent medications increased. For intervention patients with
hypertension only, the odds ratio (OR) was 1.12 (95% CI 0.99, 1.25; p = 0.06) and for controls 1.13 (1.05, 1.21; p =
0.002). We observed no statistically significant differences in the change in the prescribing of specific
antihypertensive agents between the intervention and control groups. The use of agents acting on the renin-
angiotensin-aldosterone system increased in all subgroups (hypertension only intervention patients OR 1.19 (1.06,
1.34; p = 0.004) and controls OR 1.24 (1.15, 1.34; p < 0.0001).
Conclusions: A multifaceted guideline implementation intervention does not necessarily lead to significant
changes in prescribing performance. Rigorous planning of the interventions and quality projects and their
evaluation are essential.
Background
The association between high blood pressure and the risk
of cardiovascular disease (CVD), such as stroke, is well-
established [1-3]. Among the Finnish working age popu-
lation, the estimated prevalence of hypertension was
almost 50% in 1997, after which blood pressure levels
declined until 2002 [4-7]. During the last decade, the use
of antihypertensive drugs has continuously increased [8].
However, as in other European countries, only around
every third hypertensive Finn achieves the recommended
blood pressure level (< 140/90 mmHg) [4,9-12]. Further-
more, antihypertensive drug therapy is not in line with
the current guidelines [9,13,14]; in Finland in particular
the percentage of patients using beta-blocking agents is
high irrespective of the type of co-morbidities [9]. In
Finland, national evidence-based guidelines have been
developed and published since 1994 in the Current Care
Guideline Programme for both primary and secondary
care, under the auspices of the Finnish Medical Society
Duodecim.
In order to facilitate the adaptation of new research
evidence, experts search, evaluate, and gather research
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lishing a guideline, unaccompanied by any other actions,
is considered guideline dissemination. The next step
towards proper implementation is distribution through
various channels. Distributing educational material
improves the care process by a median of 8% [15]. How-
ever ‘real-life implementation’ based on several, often
simultaneous activities remains challenging. Single inter-
ventions typically have a small to moderate effect, with
reminders proven to be the most effective (mean
improvement in process of care 14%). Two Cochrane
reviews show that outreach visits, as well as audit and
feedback, exert a small, consistently positive impact on
changes in prescription practices [16,17]. The more per-
sonalised the prescription intervention in a primary care
setting is, the more effective it is thought to be [18,19].
One systematic guideline implementation study aiming
at improving antihypertensive drug prescribing was con-
ducted in Norway in 2002 [20-23]. This multifaceted inter-
vention (educational outreach visits, audit and feedback,
reminders, and risk assessment tools) was intended to
increase the prescribing of thiazides as the first-line drugs
for newly treated patients with hypertension. Compared
with a control group exposed to passive dissemination, the
prescription of thiazides increased significantly in the
intervention group; however, intervention costs were the
equivalent of twice the savings gained during the one-year
follow-up.
We conducted a multifaceted quality improvement pro-
gramme (education, audit and feedback, local care path-
way and information) in Finland’s primary care setting,
aimed at implementing the existing guidelines and
improving the clinical process in the prevention and care
of cardiovascular diseases. We have described the inter-
vention and the results concerning the process measures
earlier [24,25]. Now we analyse the detailed effects of the
intervention; the impact of the comprehensive implemen-
tation of the hypertension guidelines on the prescription
of antihypertensive drugs in a controlled before and after
design.
Methods
Setting
During the study period of 2002-2003, primary health
care in Finland was mostly provided in municipal health
centres run by salaried personnel. Practices were
arranged either through the list system or the conven-
tional system, whereby appointments could be arranged
with any doctor working in a health centre. Of Finland’s
total population of 5.2 million in 2001 66% used public
primary care services at least once [26]. Occupational
health care and the private sector complemented pri-
mary health care services.
Intervention
The Helsinki Prevention Programme was carried out in
2002-2003 at the Helsinki Health Centre, which covers
population of 0.56 million [24]. The programme was
aimed at local implementation of the national guidelines
related to the prevention of, and care for, CVDs (hyper-
tension, dyslipidaemia, obesity, diabetes and smoking).
From each of the city’sh e a l t hc a r eu n i t s( n=3 1 ) ,a
voluntary physician-nurse pair was recruited. They were
trained as local experts in the prevention of CVDs and to
act as intrinsic peer facilitators in guideline implementa-
tion. The two-year facilitator intervention consisted of 16
educational sessions (lectures, workshops, patient cases,
and role modelling) and 12 distance learning tasks (audit-
ing processes, self-audits, planning preventive activities,
and educations for co-workers). The intervention has
been described in detail earlier [24]. During the time of
the intervention, patients were listed according to the
place of residence.
During the first year of the programme, the implemen-
tation focused on the hypertension guideline (Figure 1).
The facilitators tailored a local care pathway for hyper-
tension patients (a flowchart on the basis of the Current
Care Guidelines) and further implemented the care path-
way in interactive workshops in their own health care
units [25]. In the flowchart, the diagnosis of hyperten-
sion, examinations and follow-up schema according to
both total cardiovascular risk and blood pressure limits
were described. The responsibilities of different health
professionals and organisations were also described and
the tasks were divided. Recommendations for antihyper-
tensive medication (Table 1) were discussed in lectures
and workshops; patient case reports were used to facili-
tate these discussions. Three core messages of the guide-
line were emphasised: 1) according to research evidence
all four main antihypertensive drug groups are consid-
ered equally effective in lowering blood pressure, 2) drug
choice should be based on the severity of hypertension,
concomitant complications, the patient’s other cardiovas-
cular risk factors and co-morbidities, and 3) over half of
all hypertension patients need multiple concurrent medi-
cations to reach treatment targets [27]. Furthermore, the
financial aspects of the various drug choices were
discussed.
Participating doctors and patients
Those 25 facilitator doctors who gave permission for data
collection related to their prescriptions are referred to as
intervention general practitioners (GPs). Voluntary con-
trols (referred to as control GPs) were recruited from
two large cities (Kuopio with the conventional and Turku
with the list system). Two contact persons performed the
recruitment, and 53 GPs gave permission (Kuopio n = 31
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Distance learning task I
With a multiprofessional team
gather information:
1. What kind of handouts is 
available for patients who 
need lifestyle interventions
2. Limits for BP, cholesterol and 
blood glucose values for 
nurses to consult GPs
3. Limits for BP, cholesterol and 
blood glucose for initiation of 
drug treatment
Distance learning task II
1. Draft an ideal care pathway for a 
hypertension patient at your own 
primary care unit
2. Organise an audit for blood 
pressure measurements 
3. Arrange workshops at your own 
unit on topics of education I
Distance learning task V
1. Description of the 
programme at own unit 
(workshops, approximation of 
time used for the programme, 
successes)
2. Description of the state of 
preventive work at the unit
3. Vision of a preventive event 
for the population
Education I, 2 days
•Prevention, general
•Hypertension, CC guideline
•Lifestyle changes
•Patient cases (hypertension)
•Distance learning task, results
•Drafting the hypertension care pathway
•Dyslipidemia CC guideline
•Leading the change
Start event at each health care unit
•Programme promotion and 
motivation
•Analysis of the state of preventive 
work
•CV risk factor recording, self-audit 
from patient record
•Cause-effect analysis on CV 
patients’ variable treatment practices
Education II, ½ day
•Feedback on blood pressure audit
•Drafting the hypertension care 
pathway further
•Chain of care in Diabetes
•Leading the change
•Communication skills
Education III, ½ day
•Presenting the final 
hypertension care pathway
•Division of tasks, 
implementation of care 
pathway
•Physical exercise
•Motivation
•Feedback on diabetes 
audit Education V, ½ day
•Blood pressure treatment in Helsinki 
vs. other parts of Finland
•Leading the change
Education IV, ½ day
•Dyslipidemia, CC guideline
•Feedback on dyslipidemia audit
•Drafting the dyslipidemia care 
pathway
•Patient cases (dyslipidemia, total 
CV risk)
Distance learning task III
1. Make a plan for a regular 
control visit for a diabetic 
patient (content of visits, 
laboratory tests and task 
dividing)
2. Organise audit on diabetes 
treatment levels
Distance learning task IV
1. Organise audit on 
cholesterol treatment levels
2. Risk analysis on task-
dividing
Motivation of the 
managers
Recruitment of 
facilitators and 
planning the 
programme
Education VI, ½ day
•The programme in 2002
•Plans for the year 2003
Figure 1 Description of the intervention during the year 2002. Abbreviations: CV, cardiovascular; CC, Current Care; GP, general practitioner;
BP, blood pressure.
Table 1 Recommendations for antihypertensive drug choices according to co-morbidities, the Current Care
Hypertension guideline 2002 [27]
First line medication Second choice Special considerations
Hypertension Thiazide diuretics
ACEI
Beta-blocking agents
ARB Diuretics or CCBs if isolated systolic blood pressure
Diabetes ACEI
Diuretics
Beta-blocking agents
CCBs
CHD Beta-blocking agents Diuretics
CCBs
Heart failure ACEI
Diuretics
Beta-blocking agents
ARB
Arrhythmia Beta-blocking agents
CCBs
Depends on the type of arrhythmia
Dyslipidaemia Do not have significance to the drug choice
Asthma or COPD Diuretics
CCBs
ACEI
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor inhibitor; CCBs, calcium channel blockers; CHD, coronary heart disease;
COPD, chronic obstructive pulmonary disease.
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Page 3 of 12and Turku n = 22). At baseline, all participating physi-
cians completed a questionnaire, giving background
information and their self-rated motivation to treat
patients in accordance with the Current Care Guidelines
(based on the Finnish school grading system of 4-10). In
this report, patients who were dispensed antihypertensive
drugs during the study period in 2001 or 2003, as pre-
scribed by the intervention or control GPs, are referred
to as intervention and control patients for the respective
year.
Data source
The data on prescriptions was drawn from the National
Prescription Register, managed by the Social Insurance
Institution (SII). The register includes data on reim-
bursed medicines, and the patient’s date of birth, gender
and residential area [8,28]. In the register, the dispensed
drugs are identifiable by the ATC classification code [29].
Each person can be identified through a unique personal
ID and each doctor has a personal code. The register
does not contain information on the purpose of the
medication.
Reimbursement is divided into Basic and Special
Refunds. Drugs with an approved reasonable wholesale
price, including all antihypertensive drugs, are reimbursed
with the Basic Refund (50%) for any person living in the
community. Patients with certain severe long-term dis-
eases such as coronary heart disease (CHD), chronic
hypertension or diabetes are entitled to a higher rate of
refund (the Special Refund, 75 or 100%) and can be identi-
f i e df r o mas e p a r a t eS I Ir e g i s t e r .T ob ee l i g i b l ef o rt h e
Special Refund 1) the patient’s condition must meet expli-
cit, predefined criteria, 2) the patient must apply for the
Special Refund using the necessary certificate completed
by the treating physician and a SII’s expert physician eval-
uates whether the criteria are met, and 3) the preparation
dispensed must qualify for the Special Refund. Conse-
quently, eligibility for a Special Refund for a certain disease
can be used as a proxy for morbidity, although all patients
potentially eligible do not apply for it. Overall, reimbursed
drugs can be dispensed for a maximum period of three
months for a single purchase.
There was no legal requirement for ethics committee
approval since the intervention was directed at profes-
sionals, only unidentifiable patient data were used, and
the patients were not contacted.
Outcome measures
The main outcomes were: 1) the proportion of patients
treated with two or more concurrent antihypertensive
drugs, 2) the proportion of patients with CHD treated
with beta-blocking agents, 3) the proportion of patients
with diabetes treated with RAAS, and 4) the proportion
of patients with hypertension only treated with diuretics.
The outcomes were measured during a three-month per-
iod before the first year of intervention, 1 January to 31
March 2001, and the respective period in 2003, after the
intervention. The results are reported separately for
hypertension patients with 1) hypertension only, 2) CHD,
and 3) diabetes with or without CHD (Figure 2).
Reimbursed antihypertensive prescriptions issued by the
participating physicians and dispensed from 1 January to
31 March 2001 and 2003 were retrieved from the Prescrip-
tion Register, utilising doctors’ personal codes. Irrespective
of the refund category (Basic or Special Refund), all pre-
scriptions for the following drugs were included: miscella-
neous antihypertensives (ATC code C02), diuretics (C03),
beta-blocking agents (C07), calcium channel blockers
(CCBs) (C08) and agents acting on the renin-angiotensin-
aldosterone system (RAAS) (C09). Dispensations were
linked with a patient through the unique personal ID and
converted to represent the drugs used by each patient
(Figure 2). Consequently, the patient population, i.e. the
denominator, for the study consisted of persons who were
dispensed antihypertensive drugs in the first quarter of
2001 or 2003. We did not analyse previous use of antihy-
pertensive drugs and therefore could not separate new
users in the analysis. Due to the cross-sectional design, a
patient’s medication list could include continuously used
drugs, new drugs added to the previous therapy as well as
drugs discontinued during the specific three-month time
window.
Statistical analysis
Using logistic regression, adjusted odds ratios (ORs) for
the use of specific antihypertensive agents (diuretics,
beta-blocking agents, CCBs or RAAS) and the use of two
or more concurrent antihypertensive drugs were esti-
mated, comparing patients treated after the intervention
with those treated before it. The 95% confidence intervals
(95% CI) were calculated. Separate models were adapted
for the intervention and control patients. Using data on
both intervention and control patients, the statistical sig-
nificance of the difference in the ORs between the groups
was estimated by including an interaction term between
time (after versus before) and group (intervention versus
control) in the model. Because of the clustering of
patients by physician, generalized linear mixed models
were used in estimation, considering the physician as a
random effect. All models were adjusted for the patients’
age (continuous variable) and gender. The data was ana-
lysed using SPSS 15.0 for Windows and SAS 9.2.
The intervention was a pragmatic quality project and
was based on the development needs of one organisa-
tion. Therefore the before and after design was chosen
and power analysis was not performed ap r i o r i .T og i v e
the reader insight into the clinical significance of the
results, confidence intervals for ORs are presented.
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Doctors
At baseline, the mean age of the intervention general prac-
titioners (GPs) was 42 years and that of the control GPs 43
years. The number of female GPs was 22 (88%) and 33
(62%), respectively. The mean length of experience in pri-
mary care was 13 and 15 years. Participating GPs rated
themselves as highly motivated to treat patients in
accordance with the Current Care Guidelines (based on
the Finnish school grading system from 4 to 10, median of
9 for both groups).
Patients and the outcome measures
A total of 2,872 and 3,865 intervention patients and
7,066 and 8,693 control patients purchased antihyper-
tensive agents in the data collection periods in 2001 and
25 intervention and
53 control GPs
Identification of dispensed prescriptions
(1st January trough 31st March 2001 and 2003)
from National Prescription Register
Antihypertensives (ATC code C02)
Diuretics (C03)
Peripheral vasodilators (C04)
Beta-blocking agents (C07)
Calcium channel blockers (C08)
Agents acting on the RAAS (C09)
Data for each prescription 
ATC code 5th level
Generic preparation
Disease number code (Code for Special Refund)
Patient information (patient code, gender and age)
Patient specific data
1. Combination drugs were recoded into separate chemical subgroups
2. Duplicate purchases deleted if at least one prescription
Antihypertensives (C02)
Diuretics (C03)
Peripheral vasodilators (C04)
Beta-blocking agents (C07)
Calcium channel blockers (C08)
Agents acting on the RAAS (C09)
1) Hypertension only
No redeemed prescriptions for
diabetes (ATC A10)
or
under the special refund for CHD
Analysis in patient subgroups
3) Hypertension and diabetes
Redeemed prescriptions for
diabetes (ATC A10)
2) Hypertension and CHD
Redeemed prescriptions
under the special refund for CHD 
and
No redeemed prescriptions for
diabetes (ATC A10)
Figure 2 The conversion of the prescription data to represent each patient’sd r u g s . Abbreviations: GP, general practitioner; ATC,
Anatomical Therapeutic Chemical; RAAS, renin-angiotensin-aldosterone system; CHD, coronary heart disease.
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median age was 70 or more and approximately two-
thirds were female. In all patient groups, the number of
patients receiving two or more (max. four) concurrent
antihypertensive drugs increased (Table 3). There was
no difference in the change of likelihood of receiving
two or more concurrent antihypertensive drugs versus
monotherapy between intervention and control patients
(p-values for intergroup comparisons > 0.05). The
change for diabetes patients in the intervention group,
compared to controls, was rather impressive (the per-
centage of patients receiving two or more concurrent
antihypertensive agents +7.1% units, OR 1.33; 95% CI
0.99, 1.79, p = 0.06) but it did not reach statistical sig-
nificance (p = 0.28).
Apart from diuretics in most patient groups and cal-
cium channel blockers in two groups, the number and
proportion of patients receiving specific antihypertensive
drugs increased for intervention and control patients
(Table 4). The decrease of diuretics was significant only
for control patients in the hypertension only group
(-1.8% units, OR 0.92; 95% CI 0.85, 0.99, p = 0.02).
There were no significant differences between the inter-
vention and control patients in the change of use of spe-
cific antihypertensive agents (p-values for intergroup
comparisons > 0.05). The use of beta-blocking agents
increased in intervention patients with CHD (+6.1%-
units, OR 1.39; 0.99, 1.96, p = 0.06). In the case of
RAAS, the increase was mainly due to the increase in
the use of angiotensin II receptor blockers (ARBs); for
intervention patients with hypertension only the ORs
were 1.61 (1.47, 1.78, p < 0.0001) and for control
patients 1.58 (1.41, 1.78, p < 0.0001). For diabetic
patients, the respective ORs were 2.21 (1.21, 4.04, p =
0.01) and 1.38 (0.95, 2.01, p = 0.09).
Discussion
Our findings suggest that the multifaceted comprehen-
sive implementation of a hypertension guideline did not
exert an impact on GPs’ prescribing of antihypertensive
drugs for drug-treated patients with hypertension, even
though the participating GPs rated themselves as highly
motivated to act according to the guidelines. Increased
prescribing of beta-blocking agents for patients with
CHD among intervention GPs and the increased pre-
scribing of RAAS for diabetic patients among control
GPs are more likely to reflect poor baseline adherence
to the guideline than the effects of intervention. The
observed ineffectiveness may be due to factors related to
1) intervention, 2) prescribing behaviour, or 3) study
design and the measurements.
Intervention
Planning, conducting and evaluating an extensive inter-
vention is challenging, especially when a project is a
quality programme aiming at changing healthcare pro-
cesses rather than a pure clinical study. In extensive
interventions, some aims may override others, especially
if they are perceived to be more important by the parti-
cipants [30]. In order to be adopted effectively, the aims
must be explicit and repeatedly discussed with the parti-
cipants. Our intervention focused on tailoring and
implementing a local hypertension care path based on
the national clinical guideline. The ultimate aim was to
improve the treatment of hypertension patients by fol-
lowing the recommendations of the guideline, including
drug therapy. For each session, the specific aims were
highlighted and the topics were covered several times
(Figure 1). The intervention was multifaceted, consisting
of both lecture and small group education and the
development of a local care path as well as audit and
feedback on the division of tasks and treatment levels.
Peer discussions and benchmarking were fundamental
parts of the intervention. These methods should have
had a small to modest impact on clinical practices,
including prescribing [15].
Prescribing behaviour
Prescribing is a complex behaviour simultaneously
affected by several factors of varying intensity; the new
Table 2 Characteristics of intervention and control patients in 2001 and 2003
Intervention Controls
2001 2003 2001 2003
(n = 2872) (n = 3865) (n = 7066) (n = 8693)
Age, years, median (IQR) 70 (62, 78) 71 (62, 78) 70 (61, 77) 71 (62, 78)
Patients > 65 years 1947 (67.8) 2654 (68.7) 4661 (66.0) 5915 (68.1)
Females 1823 (63.5) 2381 (61.6) 4315 (61.1) 5280 (60.8)
CDH* 320 (11.1) 440 (11.4) 950 (13.4) 1148 (13.2)
Diabetes* 302 (10.5) 456 (11.8) 612 (8.7) 828 (9.5)
Figures are number (percentage) unless otherwise stated.
Abbreviations: N, number; CHD, coronary heart disease; IQR, interquartile range.*Diagnosis of CHD was based on Special Refund code and diabetes on
antidiabetic drug (ATC A10) purchases
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Page 6 of 12Table 3 Number and proportions of patients who used two or more antihypertensive drugs concurrently and adjusted odds ratios for change
Intervention Controls Intergroup comparison
2001 2003 Adjusted* OR (95% CI) p-value 2001 2003 Adjusted* OR (95% CI) p-value Adjusted* OR (95% CI) p-value
n (%) n (%)
Hypertension
828 (36.8) 1164 (39.2) 1.12 (0.99, 1.25) 0.06 2119 (38.5) 2774 (41.3) 1.13 (1.05, 1.21) 0.002 0.99 (0.86, 1.13) 0.86
CHD
110 (34.4) 164 (37.3) 1.19 (0.87, 1.62) 0.23 292 (30.7) 389 (33.9) 1.10 (0.91, 1.33) 0.33 1.07 (0.75, 1.54) 0.70
Diabetes
144 (47.7) 250 (54.8) 1.33 (0.99, 1.79) 0.06 303 (49.5) 428 (51.7) 1.10 (0.89, 1.36) 0.38 1.22 (0.85, 1.75) 0.28
Prescription data was drawn from the national Prescription Register during a three-month period in 2001 and 2003.
Abbreviations: CHD, coronary heart disease; OR, Odds ratio; CI, confidence interval.
*Within-group analysis: Logistic regression, random effects model (physician as a random effect). Adjusted for patient’s age and patient’s sex. Reference group: patients with one antihypertensive drug.
**Intergroup analysis: Logistic regression, random effects model (physician as a random effect). A product term between time (after versus before) and group (intervention versus control) was added in the model.
Adjusted for patient’s age and patient’s sex. Reference group: patients with one antihypertensive drug.
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2Table 4 Number and proportions of patients who used specific antihypertensive drugs and adjusted odds ratios for change
Intervention Controls Intergroup comparison
2001 2003 Adjusted* OR (95% CI) p-value 2001 2003 Adjusted* OR (95% CI) p-value Adjusted** OR (95% CI) p-value
n (%) n (%)
Hypertension, N 2250 2969 5504 6717
Diuretics 886 (39.4) 1143 (38.5) 0.97 (0.86, 1.08) 0.56 2207 (40.1) 2575 (38.3) 0.92 (0.85, 0.99) 0.02 1.06 (0.92, 1.21) 0.44
Beta-blockers 982 (43.6) 1312 (44.2) 1.04 (0.93, 1.16) 0.50 2335 (42.4) 2890 (43.0) 1.03 (0.96, 1.12) 0.35 1.01 (0.88, 1.15) 0.93
CCBs 560 (24.9) 747 (25.2) 1.04 (0.92, 1.18) 0.55 1349 (24.3) 1682 (25.0) 1.04 (0.95, 1.13) 0.43 0.99 (0.84, 1.14) 1.00
RAAS 738 (32.8) 1108 (37.3) 1.19 (1.06, 1.34) 0.004 1966 (35.7) 2724 (40.6) 1.24 (1.15, 1.34) <0.0001 0.96 (0.83, 1.10) 0.56
CHD, N 320 440 950 1148
Diuretics 71 (22.2) 98 (22.3) 1.02 (0.71, 1.46) 0.92 171 (18.0) 229 (19.9) 1.05 (0.84, 1.33) 0.67 0.98 (0.64, 1.50) 0.92
Beta-blockers 235 (73.4) 350 (79.5) 1.39 (0.99, 1.96) 0.06 762 (80.2) 932 (81.2) 1.13 (0.90, 1.41) 0.29 1.25 (0.83, 1.88) 0.29
CCBs 103 (32.2) 113 (25.7) 0.75 (0.54, 1.03) 0.08 203 (21.4) 261 (22.7) 1.06 (0.86, 1.31) 0.59 0.70 (0.48, 1.03) 0.07
RAAS 43 (13.4) 86 (19.5) 1.57 (1.05, 2.34) 0.03 156 (16.4) 218 (19.0) 1.16 (0.92, 1.46) 0.20 1.34 (0.85, 2.12) 0.21
Diabetes, N 302 456 612 828
Diuretics 115 (38.1) 184 (40.4) 1.10 (0.81, 1.49) 0.54 278 (45.4) 365 (44.1) 0.93 (0.75, 1.15) 0.49 1.19 (0.82, 1.72) 0.37
Beta-blockers 127 (42.1) 216 (47.4) 1.24 (0.93, 1.67) 0.15 275 (44.9) 379 (45.8) 1.03 (0.83, 1.28) 0.76 1.21 (0.84, 1.74) 0.31
CCBs 91 (30.1) 137 (30.0) 0.99 (0.72, 1.37) 0.96 148 (24.2) 223 (26.9) 1.13 (0.88, 1.45) 0.33 0.88 (0.59, 1.32) 0.54
RAAS 159 (52.6) 249 (54.6) 1.08 (0.80, 1.45) 0.64 284 (46.4) 427 (51.6) 1.27 (1.02, 1.57) 0.03 0.85 (0.59, 1.23) 0.39
Prescription data was drawn from the national Prescription Register during a three-month period in 2001 and 2003.
Abbreviations: CCBs, calcium channel blockers; RAAS, agents acting on renin-angiotensin-aldosterone system; CHD, coronary heart disease; OR, Odds ratio; CI, confidence interval.
*Within-group analysis: Logistic regression, random effects model (physician as a random effect). Adjusted for patient’s age and patient’s sex.
**Intergroup analysis: Logistic regression, random effects model (physician as a random effect). A product term between time (after versus before) and group (intervention versus control) was added in the model.
Adjusted for patient’s age and patient’s sex.
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2information in the guidelines constitutes only one of
these [31]. Among other things, both patients’ and doc-
tors’ expectations and experiences may affect prescrib-
ing, as do the marketing efforts of the pharmaceutical
industry. In our study, a decrease in use of diuretics for
patients with hypertension only and an increase in the
use of new ARBs were observed regardless of patients’
co-morbidities and the fact that the guideline did not
recommend ARBs as a first-line medication. Similarly,
in the Netherlands in late 1990’s, Grevings et al.
observed that ARB prescriptions are not related to rele-
vant co-morbidities [32].
Previous observations suggest that in order to achieve
change in prescribing practices, personal feedback should
be given to physicians [18,19]. In our intervention, GPs
were informed of the data collection related to their pre-
scribing and their consent to this was requested. How-
ever, since the intervention did not include personal
feedback on prescribing, it may have been too imprecise
to induce prescription-related change.
In other studies aiming at changing prescribing prac-
tices of antihypertensive drugs towards the guidelines,
the improvement in proportions of target prescribing has
been 5-13% units [21,33-35] and the controls have
improved as well (2-6% units). In these studies the inter-
ventions have been more individualised. In our study, the
prescribing of both the intervention and control physi-
cians changed towards the guidelines. Firstly, we did not
offer active interventions to the control GPs but they
were informed about the measurements and permission
was obtained from them. Secondly, the guideline was
published and therefore available on the internet, and
thirdly, the control GPs may have participated in local
educational activities around the newly published guide-
line. Organisational traditions seem to modify physicians’
prescription practices. Ohlsson and colleagues state that
greater similarities seem to be found amongst prescrip-
tion-related behaviour between physicians within the
same health care unit than among those from different
units [36]. In our intervention, peer discussions provided
a good opportunity to reflect on prescription practices
within the organisation, as well as its own practices
against those of peers. Multidisciplinarity may have hin-
dered the focusing of the discussion on prescribing
although such a discussion is essential when improving
organisational practices and task division.
Study design and the measurements
As the intervention was a pragmatic quality project of
one organisation, power analysis was not performed a
priori. Type II error, under-powering the study, can not
b er u l e do u t .T h e r e f o r e ,i ti sp o s s i b l et h a tw ef a i l e dt o
reach statistically significant changes even though the
intervention actually was effective. For example, two
changes in the intervention group - the percentage of
patients with diabetes receiving two or more concurrent
antihypertensive agents increased by 7.1% units (OR 1.33;
95% CI 0.99, 1.79, p = 0.06) and the percentage of
patients with CHD using beta-blocking agents increased
by 6.1% units (OR 1.39; 0.99, 1.96, p = 0.06) - nearly
reached statistical significance.
The intervention GPs, the participants in the quality
project, were voluntary. Similarly the controls were
invited on a voluntary basis, in order to reduce selection
bias. This self-selection of active GPs may reduce the
generalizability of the results to the general GP popula-
tion. Furthermore voluntary participants in studies may
be active in the adoption of new information and there-
fore correspondingly active in bringing about change.
We found no differences in measured patient character-
istics between intervention and control patients or within
either group before and after the intervention. The case-
mix in terms of age, gender and measured morbidities
probably did not affect the results as we stratified the
patients by co-morbidities. However, we did not control
for other patient-related factors such as socioeconomic
status or use of other health care services.
In Finland, the Special Refund for diabetes is often
delayed [37]: we therefore chose purchases of antidiabetic
drugs as the definition of the disease. Diagnosis of CHD
based on a Special Refund is specific, but may not be sen-
sitive. Consequently, patients with CHD may have been
misclassified into the hypertension only group. This, in
turn, may have led to an overestimation of the use of beta-
blockers as hypertension medication. Previous studies,
however, have shown that in Finland, beta-blocking agents
are preferred to other antihypertensives [9,13,38].
In the following, we will focus on measuring the impact
of an intervention accurately in the context of pharmacy
claims databases and give specific consideration to our
outcome measures in the light of the issues raised by
Maclure et al. (2006) in their review of measuring pre-
scription-related improvements in the primary care setting
[39].
We measured change in prevalence of use of various
antihypertensive medications. When measuring prescrib-
ing, the denominator, i.e. the definition of the patient
group in which the outcome is intended to be measured,
is critical. As Maclure and co-workers stated, every patient
in the denominator should be at risk of entering the
numerator [39]. Therefore, new patients visiting a physi-
cian - i.e. incident users of any antihypertensives, those
switching from one therapeutic class to another and those
adding a drug to their previous medication - would repre-
sent a more valid patient group for measuring changes in
prescribing. In our study the denominator consisted of
both new and previous users of any antihypertensive drugs
- potentially leading to the dilution of the intervention’s
Sipilä et al. BMC Family Practice 2011, 12:87
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Page 9 of 12observed effect. One explanation is that, from the clinical
point of view, there is no need for change if the drug is
effective and well tolerated, even if the treatment was not
recommended in the guideline as a first line medication.
On the other hand, because switching was not analysed
we may have overestimated the concurrent use of various
drugs. Our analysis of ACEI and ARBs as a single group
(RAAS), where switching between the drugs is usual,
diminishes this bias.
We only had data on purchased prescriptions reflecting
both doctors’ and patients’ actions. Combining patient
records and claims data would provide more valid infor-
mation on doctors’ practices. Furthermore, we retrieved
claims for the prescriptions written by the study GPs only
and may have overestimated the number of patients on
monotherapy in case other physicians prescribed hyper-
tension medication to the same patients. Finally, the dura-
tion of the follow-up and the timing of the measurements
have an influence on whether an intervention’s outcomes
and impact can be detected [39]. In Finland, a prescription
is valid for one year from the date it is issued; thus,
patients with chronic conditions and a good treatment bal-
ance need to visit a doctor or renew their prescriptions at
least once a year. For this reason, our three-month time
window may reflect prescribing during the preceding year.
A longer follow-up would be needed to detect changes,
especially if only new patients were included in the
analysis.
Implications
The latest update of the Current Care Hypertension
Guideline published in 2009 included several new recom-
mendations [40]. A combination of RAAS and CCB was
recommended over one of RAAS and diuretics, especially
for high-risk patients, and combinations with beta-block-
ers were discouraged. Concern has been expressed on how
the new recommendations will be translated into clinical
practice, especially in a country characterised by the fre-
quent use of beta-blocking agents.
Practical tools, such as quality indicators, could facilitate
guideline implementation. Various indicators have been
used to measure the quality of prescribing and monitor
change [41-45]. However, the development processes of
various indicators may not be explicit [46]. Measures
should be focused, valid in every sense (content, face, con-
current, construct) and feasible. The evidence base under-
lying prescribing indicators should be clearly described;
for example, in order to have strong content validity, indi-
cators should be based on up-to-date guidelines [47,48].
They should be developed with three aims in mind: the
evaluation of clinical practices at the personal and organi-
sational level as well as providing national benchmarking
data. Comprehensive guideline implementation and health
care management could be strengthened if, when using
indicators, areas with the potential for improvement were
recognised prior to conducting implementation and qual-
ity improvement activities. Researchers would also benefit;
evidence on changing prescribing and implementation
would be easier to collect. Furthermore, claims databases
and electronic patient records should support data collec-
tion on clinical practices and patient outcomes.
Conclusions
A multifaceted guideline implementation intervention
does not necessarily lead to significant changes in pre-
scribing performance. Detected intra-group changes
toward the guideline seem more likely to reflect poor
baseline adherence than the effects of intervention. Lack
of personal feedback on prescribing may have been one
reason for ineffectiveness. Future research in this area
would benefit from larger samples to avoid the danger
of under-powering a study and to overlook the positive
effects of multifaceted interventions.
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